Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets
1 other identifier
interventional
24
1 country
1
Brief Summary
The purpose of this study is to measure the area under the curve (AUC0-48h; extent of systemic availability) and the maxi-mum concentrations (Cmax) of total serum levothyroxine (TT4, bound and free fraction) after a single pharmacological dose of 600 μg administered as tablets also containing iodine supple-ments vs. the same dose of levothyroxine administered as a reference solution without iodine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Aug 2003
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2003
CompletedFirst Submitted
Initial submission to the registry
November 2, 2011
CompletedFirst Posted
Study publicly available on registry
November 7, 2011
CompletedNovember 7, 2011
November 1, 2011
3 months
November 2, 2011
November 4, 2011
Conditions
Keywords
Study Arms (2)
with iodine
ACTIVE COMPARATORwithout iodine
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Euthyroid men
- Age: 18 - 50
- Normal values for fT4 und TSH
- Good state of health
You may not qualify if:
- Thyroid function disorders in terms of subclinical or overt hyper- or hypothyroidism
- History of thyroid function disorders
- Focal or diffuse autonomies of the thyroid gland
- Thyroid nodules \>1 ml according to sonographic examination
- Any acute or chronic illness
- Dermatitis herpetiformis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Heidelberg Universitylead
- Sanofi-Synthelabocollaborator
Study Sites (1)
Clinical Research Unit, University of Heidelberg
Heidelberg, 69120, Germany
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Clinical Research Unit
Study Record Dates
First Submitted
November 2, 2011
First Posted
November 7, 2011
Study Start
August 1, 2003
Primary Completion
November 1, 2003
Study Completion
November 1, 2003
Last Updated
November 7, 2011
Record last verified: 2011-11